A1: This was the fourth time for GSK to participate in the CIIE, the third time for GSK Consumer Health. CIIE is an important platform for us to engage with partners and consumers, collect market intelligence, exchange opinions, and communicate with key stakeholders.

A2: Facing the COVID-19 pandemic threat, hundreds of thousands of people from China and around the world gather under one roof of CIIE to talk about international business, and this is an amazing achievement. It conveys strong signal of courage and confidence towards this country and its future.

It shows China's commitment to further opening up and sends a clear welcoming message to the outside world.

A3: China is the least pandemic-hit major economy, and is the biggest growth contributor engine to the world. China's effort to increase imports show the commitment of opening-up, shows the domestic market is robust and evolving fast, and it also shows China is taking up responsibilities as a global leader. We see this as a great opportunity to tap the growth through cross-border e-commerce platform, so that we can introduce GSK Consumer Health high-quality products from other markets to meet with Chinese consumers' rising demands for quality, diversity, and personality in the everyday health market.

A4: The everyday health market in China is evolving fast with the clear trend of consumption boost for quality rather than quantity. Consumers' self-care awareness is improving, and their needs are increasing.

The Healthy China 2030 agenda sets a clear roadmap on healthcare inclusiveness, health awareness, and self-care management, in which we see opportunities that GSK Consumer Health can play well.

A5: Indeed. China is a most-improved place in the ease of doing business in the World Bank report. This shows in our experience doing business with China and in China. We are one of the beneficiaries of China's efforts to protect our intellectual property. Therefore, we have confidence to see further improvements in many more areas.

Without reform and opening-up, China would not be what it is today, nor would it have the prospects for a brighter future. Shanghai's Pilot Free Trade Zone is a great example of bold experiment and major breakthrough in opening-up.

Useful experiences gained at this special area are spread and applied in many more places. China is one of the two "Must-Win Markets" at our global strategy. GSK Consumer Health made its investment by setting up a company in Lin-Gang Special Area of the Shanghai FTZ this year.

This action is our vote for China's growth.